Last updated: February 19, 2026
This report analyzes the patent landscape and projected market trajectory for TRIAVIL 4-10, a fixed-dose combination drug. Current patent protections are analyzed, alongside key competitors, projected market share, and potential regulatory hurdles.
What is TRIAVIL 4-10 and its Therapeutic Area?
TRIAVIL 4-10 is a prescription medication comprising two active pharmaceutical ingredients: amitriptyline hydrochloride and perphenazine, in a 4 mg/10 mg ratio. This combination is indicated for the management of moderate to severe anxiety and depression, often co-occurring conditions. Amitriptyline hydrochloride is a tricyclic antidepressant (TCA) that works by increasing the levels of certain neurotransmitters in the brain, such as serotonin and norepinephrine. Perphenazine is a typical antipsychotic that functions by blocking dopamine receptors. The synergistic action of these two agents in TRIAVIL 4-10 targets both mood elevation and the management of anxiety-related symptoms. The drug was first approved by the U.S. Food and Drug Administration (FDA) on December 20, 1961.
What is the Current Patent Status for TRIAVIL 4-10?
The original composition of matter patents for the individual components of TRIAVIL 4-10, amitriptyline and perphenazine, expired decades ago. As a fixed-dose combination, TRIAVIL 4-10 has also been subject to patent expirations related to its specific formulation and manufacturing processes.
- Original Composition of Matter Patents: Expired for both amitriptyline and perphenazine.
- Formulation Patents: Patents covering the specific ratios and excipients used in TRIAVIL 4-10 have largely expired.
- Manufacturing Process Patents: Any patents related to specific synthesis routes or production methods for TRIAVIL 4-10 have also expired or are nearing expiration.
- Evergreening Attempts: While no specific ongoing patent litigation or recent "evergreening" efforts directly related to TRIAVIL 4-10 have been identified in recent public dockets, pharmaceutical companies historically pursued such strategies for older drugs through new indications or delivery mechanisms. Given TRIAVIL 4-10's established market presence and lack of novel delivery mechanisms, such efforts are unlikely to be a significant factor.
Key Date: The U.S. Patent and Trademark Office (USPTO) database indicates no active patents specifically claiming the TRIAVIL 4-10 fixed-dose combination. Generic manufacturers can legally produce and market the drug once originator patents expire.
Who are the Key Competitors for TRIAVIL 4-10?
The competitive landscape for TRIAVIL 4-10 is characterized by the availability of its individual components and generic versions of the fixed-dose combination.
Generic Manufacturers
Multiple generic pharmaceutical companies manufacture and market amitriptyline and perphenazine, as well as the fixed-dose combination itself. These companies compete primarily on price.
- Teva Pharmaceuticals: A major global generic drug manufacturer with a broad portfolio, including psychotropic medications.
- Mylan N.V. (now Viatris): Another significant player in the generics market, offering a wide range of affordable medications.
- Sun Pharmaceutical Industries Ltd.: An Indian multinational pharmaceutical company with a substantial presence in generic drug production.
- Apotex Inc.: A Canadian pharmaceutical company known for its generic drug offerings.
- Amneal Pharmaceuticals LLC: A U.S.-based manufacturer of generic and specialty pharmaceuticals.
Off-Label and Alternative Therapies
While TRIAVIL 4-10 is prescribed for anxiety and depression, physicians may also prescribe alternative treatment regimens.
- Selective Serotonin Reuptake Inhibitors (SSRIs): Drugs like fluoxetine, sertraline, and escitalopram are widely used as first-line treatments for depression and anxiety due to their generally favorable side effect profiles compared to TCAs.
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs): Medications such as venlafaxine and duloxetine offer a dual mechanism of action and are also common alternatives.
- Other Tricyclic Antidepressants (TCAs): Older TCAs may be used, though often with a higher risk of side effects.
- Atypical Antipsychotics: For more severe or treatment-resistant conditions, atypical antipsychotics might be used as adjunct therapy, but rarely as a direct replacement for the entire TRIAVIL 4-10 combination.
- Benzodiazepines: While effective for acute anxiety, their long-term use is discouraged due to dependence risks.
- Psychotherapy: Cognitive Behavioral Therapy (CBT) and other forms of talk therapy are standard non-pharmacological treatments for anxiety and depression.
What is the Projected Market Share and Revenue for TRIAVIL 4-10?
TRIAVIL 4-10, under its original brand name (e.g., Triavil), has experienced significant market erosion due to patent expirations and the rise of generic competition and newer drug classes.
- Current Market Position: TRIAVIL 4-10 is largely a commoditized product. Its market share is dominated by generic versions, with the originator brand holding a negligible portion. The drug is prescribed less frequently as a first-line therapy due to the development of SSRIs and SNRIs with improved safety profiles.
- Projected Market Share: The market share for TRIAVIL 4-10 (both branded and generic) is expected to remain stable or slightly decline. Its use is primarily confined to patients who have historically responded well to the combination, or in specific clinical scenarios where older agents are deemed appropriate.
- Estimated Total Market Value (TRIAVIL 4-10 combination, all manufacturers): Approximately $20 million to $40 million annually in the United States. This figure is an estimate, as specific market data for older, largely genericized drugs is not always granularly reported.
- Projected Annual Growth Rate: -2% to 0% for the next five years.
- Revenue Trajectory: Revenue for TRIAVIL 4-10 is primarily driven by volume rather than price, with generic manufacturers capturing the vast majority of sales.
- Originator Brand (historical peak): Estimated to have generated over $100 million annually at its peak.
- Current Originator Brand Revenue: Likely less than $1 million annually in the U.S.
- Generic Revenue: The bulk of the estimated $20 million-$40 million market value.
Factors influencing market share:
- Prescriber familiarity and patient history: Patients who have been on TRIAVIL 4-10 for extended periods and have not experienced adverse effects are likely to remain on it.
- Cost-effectiveness: Generic versions are highly cost-effective compared to newer antidepressants.
- Side effect profile: The combination of a TCA and a typical antipsychotic carries a higher burden of side effects (e.g., anticholinergic effects, sedation, weight gain, extrapyramidal symptoms) compared to newer agents, limiting its use in treatment-naïve patients.
- Competition from newer drug classes: SSRIs and SNRIs have largely replaced TCAs and older antipsychotics as first-line treatment for most anxiety and depression cases.
What are the Key Regulatory Considerations and Potential Challenges?
TRIAVIL 4-10, as an older drug with an established regulatory history, faces different challenges than novel therapeutics.
FDA Approvals and Labeling
- Original Approval: TRIAVIL 4-10 received initial FDA approval on December 20, 1961.
- Labeling Updates: The drug's labeling has been updated over time to reflect evolving understanding of its risks and benefits. Post-marketing surveillance and pharmacovigilance have led to the inclusion of boxed warnings and updated safety information.
- Indications: The primary indications remain anxiety and depression. Off-label uses may exist but are not formally recognized or promoted.
Generic Drug Approval Process
- Abbreviated New Drug Application (ANDA): Generic manufacturers seek FDA approval through the ANDA process. This requires demonstrating bioequivalence to the reference listed drug (RLD).
- Bioequivalence: Generic versions of TRIAVIL 4-10 must prove that they are absorbed into the bloodstream at the same rate and to the same extent as the RLD. This is typically achieved through pharmacokinetic studies.
- Quality Standards: Generic manufacturers must adhere to Current Good Manufacturing Practices (cGMP) to ensure the quality, safety, and efficacy of their products.
Potential Challenges
- Manufacturing and Supply Chain: Ensuring a consistent and reliable supply chain for the individual active pharmaceutical ingredients and the finished product can be challenging for older, lower-margin drugs. Sourcing APIs may involve multiple global suppliers.
- Post-Market Surveillance: The FDA continuously monitors drug safety through pharmacovigilance. Any newly identified safety signals or adverse events associated with amitriptyline or perphenazine, or their combination, could lead to labeling changes or restrictions.
- Competition and Pricing Pressure: The market is highly competitive, with numerous generic manufacturers driving down prices. This limits profit margins and can make it difficult for any single manufacturer to achieve significant market dominance.
- Therapeutic Inertia: While a challenge for newer drugs, TRIAVIL 4-10 benefits from therapeutic inertia among prescribers and patients who are familiar with and have had positive experiences with it, leading to continued, albeit limited, demand.
- Competition from Newer Agents: The most significant challenge is the clinical preference for newer antidepressants with better safety and tolerability profiles, which restricts the growth potential and overall market size for TRIAVIL 4-10.
What are the Key Takeaways?
TRIAVIL 4-10 is a mature pharmaceutical product with expired patents, primarily sustained by generic competition. Its market share is modest and expected to remain stable or decline due to the availability of newer, safer alternatives for anxiety and depression. The therapeutic niche for TRIAVIL 4-10 is limited to patients with established treatment histories or specific clinical needs. Revenue is driven by volume, with low profit margins for manufacturers. Regulatory considerations focus on maintaining GMP standards and adhering to post-market surveillance requirements.
Frequently Asked Questions
-
What is the mechanism of action for TRIAVIL 4-10?
TRIAVIL 4-10 combines amitriptyline hydrochloride, a tricyclic antidepressant, which increases neurotransmitter levels in the brain, with perphenazine, a typical antipsychotic that blocks dopamine receptors. This combination targets both mood regulation and anxiety symptoms.
-
Are there any active patents protecting TRIAVIL 4-10?
No, the original composition of matter patents for amitriptyline and perphenazine have expired, and patents covering the specific formulation and manufacturing processes of TRIAVIL 4-10 have also expired.
-
What are the primary side effects associated with TRIAVIL 4-10?
Common side effects include anticholinergic effects (dry mouth, constipation, blurred vision), sedation, dizziness, weight gain, and potentially extrapyramidal symptoms (movement disorders) due to the perphenazine component.
-
Is TRIAVIL 4-10 still prescribed as a first-line treatment?
TRIAVIL 4-10 is generally not considered a first-line treatment for anxiety and depression. Newer drug classes, such as SSRIs and SNRIs, are preferred due to their more favorable safety and tolerability profiles.
-
What is the estimated annual market value for TRIAVIL 4-10 in the U.S.?
The estimated total annual market value for TRIAVIL 4-10, including all generic manufacturers, is between $20 million and $40 million in the United States.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drug Search. Retrieved from [FDA Website - Accessed for drug approval dates and basic information]
[2] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from [USPTO Website - Accessed for patent status confirmation]
[3] Pharmaceutical Industry Market Research Reports (various publishers, proprietary data). (n.d.). Market size and competitive landscape data for psychotropic medications.
